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ABSTRACT
Metoclopramide is commonly used to treat vomiting caused by seasickness and acute gastroenteritis on 
cruise ships and serious adverse effects have not been reported from use at sea. We report severe long
-lasting adverse effects in a young female seafarer following short-term, low-dose use of metoclopramide.
During rough seas a 25-year-old female musician on a cruise vessel presented with nausea and vomiting. 
She was given intramuscular metoclopramide 10 mg and diphenhydramine 25 mg. Vomiting stopped after 
the injections, but she felt tired, confused and dizzy. She then had been taking metoclopramide 5–10 mg 
a day, but stopped after a total per oral dose of 30 mg as she developed disturbing symptoms that she 
related to the medication, including dizziness, anxiety, fatigue, depression and involuntary movements 
(twitches, jerks, ticks, and tremors of the eyelids, tongue, neck, fingers, arms and legs). Neurological exa-
mination, blood tests, electrocardiography and magnetic resonance imaging of the brain were all normal. 
Although gradually reduced in strength and frequency, the adverse effects were very disturbing for about 
10 months, but at 13 months she was almost fully recovered.
For many years numerous vomiting sea travellers have been successfully treated with a single parenteral  
10 mg dose of metoclopramide. There are no obvious reasons why our previously healthy patient experien-
ced such serious and long-lasting side effects after low-dose, short-term metoclopramide administration. 
Until more is known, metoclopramide should be reserved for debilitating cases — and only be given after 
other remedies have been tried and found ineffective. 
(Int Marit Health 2014; 65, 1: 16–19)
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INTRODUCTION
Vomiting is an unpleasant and sometimes debilitating 
symptom of motion sickness and acute gastroenteritis, 
2 conditions that can easily ruin the cruise for ill passengers 
and represent a safety hazard when officers and crew are 
affected. Severely seasick patients have been found to 
respond quickly to a single dose of parenteral metoclopra-
mide [1], which has been widely used against vomiting in 
the international cruise industry. Adverse effects have not 
been reported from use at sea, but land reports show an 
increased risk for tardive dyskinesia with duration of treat-
ment and total cumulative dose. This caused the European 
Medicines Agency in 2013 to recommend changes to the 
use of metoclopramide, including narrowing the indications 
for use and restricting the maximum daily dose to a total 
of 30 mg for a maximum of 5 days in adults [2]. We report 
severe adverse effects in a young female seafarer following 
short-term, low-dose use of metoclopramide.
CASE REPORT
A 25-year-old female musician on a cruise vessel had 
a non-alcoholic beverage (mango lassi) ashore, later drank 
a few glasses of wine aboard, which was unusual for her, 
and when she went to bed, she felt quite dizzy. During that 
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night the sea was rough and in the early morning she pre-
sented in the Medical Centre aboard with vertigo, nausea 
and vomiting. She was given intramuscular metoclopramide 
10 mg and diphenhydramine 25 mg. Immediately after the 
injections she felt very tired and confused. The vomiting 
stopped, but vertigo persisted. She had been sleeping most 
of the day. In the afternoon her condition was diagnosed as 
possible gastroenteritis and metoclopramide tablets, 10 mg 
twice a day, were prescribed. Shortly after taking only 
1/2 tablet (5 mg), she felt faint and anxious, but brushed this 
off as ‘just being sick’. After taking another 5 mg at night she 
felt very anxious, dizzy and weak, but also like her body was 
about to explode. The next day she felt just as bad, thought 
she was still seasick and took 5 mg metoclopramide twice 
that day. The third day she did not take any metocloprami-
de. The fourth day she took 10 mg metoclopramide in the 
evening, and shortly after she had irrational, compulsive 
suicidal thoughts that terrified her; she felt her heart racing 
and had strange somatic sensations, but at that point she 
believed that her symptoms were caused by the medication. 
Therefore, after a total of 40 mg metoclopramide (10 mg 
intramuscular + 30 mg by mouth) administered over 4 days, 
metoclopramide was stopped. However, she continued to 
experience disturbing symptoms that she related to the 
medication almost every day, including dizziness, anxiety, 
and depression, as well as involuntary movements (twitches, 
jerks, ticks, and tremors of the eyelids, tongue, neck, fingers, 
arms and legs) lasting seconds to minutes (Table 1) [3]. 
She ‘took a lot of diphenhydramine’ at first, and later oc-
casionally, which helped her to sleep, but her mental and 
somatic symptoms continued. She was able to work, but 
felt at times that she did not have proper control over her 
finger movements while playing her instrument. 
Her weight was 56 kg. Her vital signs, neurological exam, 
blood and urine chemistry, and electrocardiography done 
on board were normal. 
She was referred to a neurologist consultant in port 
who agreed with the ship’s diagnosis of adverse metoclo-
pramide effects. An magnetic resonance imaging stroke 
screen was normal. 
She had previously been healthy and did not use any 
medications or drugs. At the age of 13 she had been in 
a serious traffic accident and afterwards received post-
traumatic stress syndrome counselling for years.
For about 10 months after metoclopramide she still 
experienced anxiety, near-panic attacks, nightmares, fatigue 
and episodes of depression. The involuntary movements 
were gradually reduced in strength and frequency. How-
ever, at 13-month-follow-up she was optimistic regarding 
a complete recovery: only slight mental dullness remained, 
she slept well and felt only rarely ‘some really tiny twitches 
all over my body’.
Table 1. Twenty-three adverse effects experienced by our pa-
tient — from a list of 38 rare metoclopramide side effects that 
should cause patients to check with their doctor immediately if 
any of them occurs, according to US National Library [3]
Abdominal or stomach pain or tenderness 
Chills
Difficulty with breathing
Difficulty with speaking or swallowing
Dizziness or fainting
Fast or irregular heartbeat
General feeling of tiredness or weakness
Headache (severe or continuing)
Increased sweating
Lip smacking or puckering
Loss of appetite
Loss of bladder control
Mask-like face
Muscle spasms of the face, neck, and back
Nausea and vomiting
Rapid or worm-like movements of the tongue
Tic-like or twitching movements
Trembling and shaking of the hands and fingers
Twisting movements of the body
Uncontrolled chewing movements
Uncontrolled movements of the arms and legs
Weakness of the arms and legs
Yellow eyes or skin
DISCUSSION
The reason for our patient’s initial dizziness, nausea and 
vomiting is not certain, but may have been a combination 
of rough seas, acute gastroenteritis and alcohol. The do-
pamine antagonist metoclopramide has both central (anti-
dopamine-2 anti-serotonin 5-HT3) and peripheral (serotonin 
5-HT4-antagonistic) properties. The former is deemed to 
reduce nausea and the latter to promote coordinated gastric 
propulsion, both quite desirable effects in motion sickness 
[1]. Medication by mouth does not work when vomiting has 
started. Although parenteral antiemetic medication has not 
been properly tested for vomiting at sea, metoclopramide 
has since the 1970s been the antiemetic drug-of-choice 
for adults on vessels with Scandinavian ship’s doctors and 
nurses [1]. Uniform striking relief of debilitating seasickness 
is usually seen within minutes after slow intravenous ad-
ministration of 10 mg of metoclopramide, and side effects 
have not been considered a problem on cruise ships. While 
some patients have reported mild fatigue after the injection, 
the sedative effect appeared to be far less than after pro-
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methazine. Promethazine is an antihistamine widely used 
at sea as a parenteral antiemetic, after which sedation is 
considered therapeutic (‘a blessing!’) by seasick passengers 
who just want to ‘sleep it off’, preferably until the next port. 
One possible reason for not seeing more side effects on 
cruise ships might be that single metoclopramide injections 
are usually followed up by meclizine tablets once the urge 
to vomit had subsided. A widely used and well-documented 
antihistamine used against nausea and vertigo, meclizine 
has similar anticholinergic effects as diphenhydramine, 
which is recommended for extrapyramidal symptoms and 
for overdose from metoclopramide [4]. 
However, our patient received both intramuscular me-
toclopramide and intramuscular diphenhydramine at the 
same time because of vertigo, nausea and vomiting. Vo-
miting stopped, but the dizziness persisted and was treated 
with low-dose metoclopramide by mouth. Metoclopramide 
was stopped after 4 days, during which she had taken 
a total of 30 mg. Despite this low total dose over an ultra-short 
period (lower dose and shorter duration than considered 
acceptable by the European Union Committee [2] and US 
Food and Drug Administration (FDA) [4]), she experienced 
a plethora of very upsetting neurologic side effects that 
haunted her almost daily for about 10 months. Diphenhy-
dramine and biperiden have been reported to be effective 
treatments for acute metoclopramide-induced dystonia or 
akathisia [5–9]. Initially diphenhydramine helped our patient 
to sleep, but it did not have any noticeable effect on her 
long-term extrapyramidal symptoms and tardive dyskinesia. 
Although she realised that her suicidal and depressive 
thoughts, as well as her ‘out-of-her-body experiences’ were 
not real, they were very frightening and she was greatly 
bothered by her involuntary body movements. 
Despite slow, but steady general improvement, she was 
constantly worried about the ‘Black Box Warning’ that she fo-
und on the Internet. Issued by US FDA in 2009, it states that 
“In some patients, symptoms may lessen or resolve after 
metoclopramide treatment is stopped. (…) metoclopramide 
can cause tardive dyskinesia, a serious movement disorder 
that is often irreversible. (…) There is no known treatment 
(…)” [4]. Adverse effects after metoclopramide on land are 
well known, but are mostly seen after high doses and long-
term use. The absolute risk of metoclopramide-induced 
tardive dyskinesia remains unknown, but is likely to be 
less than 1% even after long-term treatment [10]. The US 
FDA ‘Black Box Warning’ recommended that indications for 
metoclopramide use should be limited and treatment should 
not exceed 3 months [4]. Unspecified nausea and vomiting 
is still an indication for metoclopramide use approved by 
the Norwegian Medicines Authority [11], but with a link to 
the European Union Committee 2013 statement advising 
against use of daily doses exceeding 30 mg and treatment 
duration of more than 5 days [12]. It is not clear why our 
previously healthy patient who used no medication or drugs 
developed a plethora of long-lasting disturbing adverse 
effects despite lower doses and shorter duration than that.
Seasick travellers are often rather mocked than pitied 
by the unaffected, but on ships seasickness is a serious 
condition that must be treated as an emergency — promptly, 
safely and effectively [1]. Seasick marine staff members 
represent a serious safety hazard, while affected hotel 
crew will provide poor or no service. Sustained vomiting 
can cause severe dehydration and is life threatening in 
persons who depend on per oral medications. Ineffective 
treatment will ruin a cruise for the passengers and may keep 
them from booking further cruises. There is no international 
agreement on seasick medications, and the indications for 
the various drugs vary within the European Union [2] and 
around the world [1]. Some medications that are considered 
drug-of-choice in some countries may be banned or not 
registered at all in another country [1]. Safe and effective 
parental remedies for severe seasickness are particularly 
important for pregnant women and watch-going seafarers, 
which calls for further research.
CONCLUSIONS
Our case is particularly disturbing for ship’s doctors 
who have successfully treated numerous distressed sea 
travellers over the years with a single parenteral dose of 
metoclopramide. When feeling in dire need of antiemetic 
medication, patients on ships are usually not very motivated 
for discussing side effects. It will therefore be mostly up to 
the physician to carefully weigh potential benefits against 
possible risks after considering contraindications and war-
nings. At this point metoclopramide should be reserved for 
debilitating cases — and only be given after other remedies 
have been tried and found ineffective. 
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